PDB11 BUDGET IMPACT ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES

Abstract

Authors

V. Kulikov R. Yagudina V. Serpik A. Kulikov

Full Text Cite This Article
Back to Volume 19, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×